Skip to Main Content

IQ-AI Ltd and announce partnership


2 mins

Business development agreement provides expanded reach of specialized software to address critical tumor response challenges.  

(SAN DIEGO) — and Imaging Biometrics®, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), join forces to increase global access to clinical diagnostic accuracy tools. The non-exclusive business development agreement expands IB’s assortment of quantitative, automated products to’ global customer base via its internal sales and marketing teams.

IB’s exclusive algorithms advance clinical understanding of brain tumor pathology by quantitatively distinguishing tumor progression from equivocal MR or CT image artifacts. IB Neuro™ provides a significant leap in magnetic resonance (MR) perfusion analysis and is the only tool of its kind to automatically generate quantitative relative cerebral blood volume (rCBV) maps independent of scanner, field strength, patient or time point. IB Delta Suite™ automates quantitative difference (Delta T1) maps using pre- and post-contrast T1 weighted MRI to help clinicians distinctly establish tumor progression and treatment effect. will additionally distribute IB StoneChecker™, which is in the final stages of FDA clearance. StoneChecker is a semi-automated kidney stone assessment tool that provides physicians with useful clinical metrics instantly using the patient’s non-contrast CT scans. The software establishes size, location, and composition of kidney stones by analyzing 32 parameters. Clinicians can use the conclusive data to help determine effective treatment options, making it a crucial tool in kidney stone management.

David Smith, CEO of IQ-AI, said, “For the first time IQ-AI’s full range of products will have direct sales representation worldwide. We are very excited about the shared revenue potential of this agreement. has a well established and rapidly growing sales and marketing team who can introduce IB’s portfolio to their existing and new clients.”

IB’s products complement’ portfolio which specializes in assessing neurological conditions, including Alzheimer’s disease, multiple sclerosis, epilepsy, and traumatic brain injury.

“We are delighted to partner with IQ-AI to help bring their innovative products to market,” said Dr. Chris Airriess, CEO of “Imaging Biometrics’ suite of products are very complementary to ours and help solve important clinical challenges faced by our global customer base.”

About develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice.’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. Please visit for further information.

About IQ-AI, Ltd

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. ( Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. Please visit for further information.